Jackpharma is well positioned to grow its business in 2022 and beyond. It accelerated its financial strength with the surge in sales of Molnaflu in Jan 2022. JPI shall invest in new launches and bring in more talents this year.
To achieve new heights, the new JPI launches will be an unprecedented portfolio of strong revenue contributors. These products will strengthen and compliment the existing portfolio. JPI will continue to invest on new talents, which include new leaders, territory managers and back-office support.
JPI values the contribution of Molnaflu and it will continue to evaluate other Covid-19 drugs. But we must set our vision in Climbing to New Heights, by harnessing the potential of our existing and new products and our people. This will sustain our growth beyond 2022.